Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | AMPD3 | Q01432 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757158 | 1.00 | PNMT (0.48) | PNMTDPP7DPP8DPP9HTR7 | |
| SCHEMBL28030549 | 0.92 | PNMT (0.51) | PNMTHTR7HTR2BNPC1RAB9A | |
| SCHEMBL3484490 | 0.87 | PNMT (0.54) | PNMTHTR7HTR2BNPC1RAB9A | |
| SCHEMBL28503693 | 0.84 | PNMT (0.43) | PNMTDPP7DPP8DPP9HTR7 | |
| Lysine SCHEMBL29220798 | 0.84 | PNMT (0.43) | PNMTDPP7DPP8DPP9HTR7 | |
| SCHEMBL5613893 | 0.84 | ACE (0.51) | PNMTDPP7DPP8ACECPB2 | |
| SCHEMBL31190266 | 0.84 | ACE (0.51) | PNMTDPP7DPP8ACECPB2 | |
| SCHEMBL2157075 | 0.84 | ACE (0.51) | PNMTDPP7DPP8ACECPB2 | |
| Hydrochloric Acid SCHEMBL31235655 | 0.83 | ACE (0.50) | PNMTDPP7DPP8ACECPB2 | |
| Hydrochloric Acid SCHEMBL28030248 | 0.83 | ACE (0.50) | PNMTDPP7DPP8ACECPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115960164-A | Preparation method and application of scorpion toxin-derived cell-penetrating polypeptide | 中国人民解放军海军军医大学 | 2023-04-14 | — | — | CN | claimed |
| CN-110950939-B | Acinetobacter baumannii Omp22 recombinant multi-antigen epitope polypeptide and application thereof | 南京医科大学第二附属医院 | 2022-05-17 | — | — | CN | claimed |
| CN-111166892-A | Biotin and cell-penetrating peptide co-mediated breast cancer targeted intelligent liposome material | 四川大学 | 2020-05-19 | — | — | CN | claimed |
| EP-3231446-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2026-01-07 | — | — | EP | disclosed |
| CN-116063379-B | EphA2 targeting polypeptides and uses thereof | 中国药科大学 | 2025-05-02 | — | — | CN | disclosed |
| EP-2911695-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2023-11-29 | — | — | EP | disclosed |
| CN-111377985-B | Compounds and conjugates, methods of making and uses thereof | 苏州瑞博生物技术股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-112386707-B | Tumor targeting polypeptide drug conjugate and preparation method thereof | 辽宁医学诊疗科技研发中心有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-113384715-B | anti-VEGF medicine containing cell penetrating peptide fusion protein, and preparation method and application thereof | 上海市第十人民医院 | 2023-08-04 | — | — | CN | disclosed |
| CN-116063379-A | EphA2 targeting polypeptides and uses thereof | 中国药科大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-115960164-A | Preparation method and application of scorpion toxin-derived cell-penetrating polypeptide | 中国人民解放军海军军医大学 | 2023-04-14 | — | — | CN | disclosed |
| US-20140120158-A1 | Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types | PALOMO LIMITED (CY) | 2014-05-01 | — | — | US | disclosed |
| EP-2560687-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | Nlife Therapeutics S.L. (ES) | 2013-02-27 | — | — | EP | disclosed |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2012-12-20 | — | — | US | disclosed |
| CN-102628044-A | RNAi modulation of APOB and uses thereof | ALNYLAM PHARMACEUTICALS INC | 2012-08-08 | — | — | CN | disclosed |
| CN-101133074-B | RNAi modulation of APOB and uses thereof | ALNYLAM PHARMACEUTICALS INC | 2012-05-30 | — | — | CN | disclosed |
| WO-2011131693-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | NLIFE THERAPEUTICS, S.L. (ES) | 2011-10-27 | — | — | WO | disclosed |
| EP-2380595-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | Nlife Therapeutics S.L. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-8041258-B2 | Process cartridge and image forming apparatus | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2011-10-18 | — | — | US | disclosed |
| CN-101133074-A | RNAi modulation of APOB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120158-A1 | Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types | SLC6A2, SLC6A3, SLC6A4 | PNMT 44/4885DPP7 2087/4885DPP8 3142/4885 |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC18A2, SLC1A1 | PNMT 881/4885DPP7 1501/4885DPP8 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.